Phase 1 and 2: Changes in laboratory measurements;Phase 1 and 2: Changes in physical examinations;Phase 1 and 2: Changes in vital signs;Phase 1 and 2: Frequency of Adverse Events;Phase 1 and 2: Frequency of Medically-Attended Adverse Events;Phase 1 and 2: Frequency of New-Onset Chronic Medical Conditions;Phase 1 and 2: Frequency of Serious Adverse Events;Phase 1 and 2: Frequency of solicited reportable local Adverse Events;Phase 1 and 2: Frequency of solicited reportable systemic reactogenicity Adverse Events;Phase 1 and 2: Grade of Adverse Events;Phase 1 and 2: Grade of of solicited reportable systemic Adverse Events;Phase 1 and 2: Grade of solicited reportable local Adverse Events;Phase 1 and 2: Presence of injection site reactions;Phase 2: Geometric mean titers (GMT) in SARS-CoV-2-specific serum neutralising antibody levels

Phase 1 and 2: Changes in laboratory measurements;Phase 1 and 2: Changes in physical examinations;Phase 1 and 2: Changes in vital signs;Phase 1 and 2: Frequency of Adverse Events;Phase 1 and 2: Frequency of Medically-Attended Adverse Events;Phase 1 and 2: Frequency of New-Onset Chronic Medical Conditions;Phase 1 and 2: Frequency of Serious Adverse Events;Phase 1 and 2: Frequency of solicited reportable local Adverse Events;Phase 1 and 2: Frequency of solicited reportable systemic reactogenicity Adverse Events;Phase 1 and 2: Grade of Adverse Events;Phase 1 and 2: Grade of of solicited reportable systemic Adverse Events;Phase 1 and 2: Grade of solicited reportable local Adverse Events;Phase 1 and 2: Presence of injection site reactions;Phase 2: Geometric mean titers (GMT) in SARS-CoV-2-specific serum neutralising antibody levels

Changes in laboratory measurements;Changes in physical examinations;Changes in vital signs;Frequency of Adverse Events;Frequency of Medically-Attended Adverse Events;Frequency of New-Onset Chronic Medical Conditions;Frequency of Serious Adverse Events;Frequency of solicited reportable local Adverse Events;Frequency of solicited reportable systemic reactogenicity Adverse Events;Grade of Adverse Events;Grade of of solicited reportable systemic Adverse Events;Grade of solicited reportable local Adverse Events;Presence of injection site reactions

Changes in laboratory measurements;Changes in physical examinations;Changes in vital signs;Frequency of Adverse Events;Frequency of Medically-Attended Adverse Events;Frequency of New-Onset Chronic Medical Conditions;Frequency of Serious Adverse Events;Frequency of solicited reportable local Adverse Events;Frequency of solicited reportable systemic reactogenicity Adverse Events;Grade of Adverse Events;Grade of of solicited reportable systemic Adverse Events;Grade of solicited reportable local Adverse Events;Presence of injection site reactions

Measurement of aspartate transaminase (AST);Assess the number of lymphocytes;Assess the percentage of neutrophil;Assess the number of neutrophil;Assess the percentage of lymphocytes;Frequency of Adverse Events;assess if there are any symptoms at the lungs;Grade of Adverse Events;assess if there are any symptoms at the lymph nodes;Frequency of solicited reportable local Adverse Events;assess if there are any symptoms at the heart;Grade of solicited reportable local Adverse Events;assess if there are any symptoms at the abdomen;assess if there are any symptoms at the skin;Frequency of solicited reportable systemic Adverse Events;Measurement of haemoglobin (Hb);Grade of of solicited reportable systemic Adverse Events;Measurement of haematocrit (HCT);Frequency of Serious Adverse Events;Measurement of red blood cell (RBC);Frequency of Medically-Attended Adverse Events;Measurement of white blood cells (WBC);Frequency of New-Onset Chronic Medical Conditions;Assess the percentage of eosinophil;Measurement of body temperature;Assess the number of eosinophil;measurement of respiratory rate;Assess the percentage of basophil;measurement of pulse rate;Assess the number of basophil;measurement of systolic blood pressure (SBP);Assess the percentage of monocytes;measurement of diastolic blood pressure (DBP);Assess the number of monocytes;assess if there are any symptoms at the head;Measurement of platelet;assess if there are any symptoms at the ears;Measurement of sodium;assess if there are any symptoms at the nose;Measurement of potassium;Measurement of chloride;assess if there are any symptoms at the throat;Measurement of bicarbonate;Measurement of blood urea nitrogen (BUN);Measurement of creatinine;Assess total protein;Measurement of albumin;Measurement of lipase;Measurement of phosphorus;Measurement of gamma-glutamyl transferase (GGT);Measurement of glucose;Measurement of creatinine phosphokinase (CPK);Measurement of calcium;Measurement of uric acid;Measurement of C-reactive protein (CRP);Measurement of alanine transaminase (ALT);Measurement of alkaline phosphatase (ALP);Assess total bilirubin;Assess estimated glomerular filtration rate (eGFR);Measurement of prothrombin time (PT);Measurement of partial thromboplastin time (PTT);Measurement of international normalized ratio (INR)

Measurement of aspartate transaminase (AST);Assess the number of lymphocytes;Assess the percentage of neutrophil;Assess the number of neutrophil;Assess the percentage of lymphocytes;Frequency of Adverse Events;assess if there are any symptoms at the lungs;Grade of Adverse Events;assess if there are any symptoms at the lymph nodes;Frequency of solicited reportable local Adverse Events;assess if there are any symptoms at the heart;Grade of solicited reportable local Adverse Events;assess if there are any symptoms at the abdomen;assess if there are any symptoms at the skin;Frequency of solicited reportable systemic Adverse Events;Measurement of haemoglobin (Hb);Grade of of solicited reportable systemic Adverse Events;Measurement of haematocrit (HCT);Frequency of Serious Adverse Events;Measurement of red blood cell (RBC);Frequency of Medically-Attended Adverse Events;Measurement of white blood cells (WBC);Frequency of New-Onset Chronic Medical Conditions;Assess the percentage of eosinophil;Measurement of body temperature;Assess the number of eosinophil;measurement of respiratory rate;Assess the percentage of basophil;measurement of pulse rate;Assess the number of basophil;measurement of systolic blood pressure (SBP);Assess the percentage of monocytes;measurement of diastolic blood pressure (DBP);Assess the number of monocytes;assess if there are any symptoms at the head;Measurement of platelet;assess if there are any symptoms at the ears;Measurement of sodium;assess if there are any symptoms at the nose;Measurement of potassium;Measurement of chloride;assess if there are any symptoms at the throat;Measurement of bicarbonate;Measurement of blood urea nitrogen (BUN);Measurement of creatinine;Assess total protein;Measurement of albumin;Measurement of lipase;Measurement of phosphorus;Measurement of gamma-glutamyl transferase (GGT);Measurement of glucose;Measurement of creatinine phosphokinase (CPK);Measurement of calcium;Measurement of uric acid;Measurement of C-reactive protein (CRP);Measurement of alanine transaminase (ALT);Measurement of alkaline phosphatase (ALP);Assess total bilirubin;Assess estimated glomerular filtration rate (eGFR);Measurement of prothrombin time (PT);Measurement of partial thromboplastin time (PTT);Measurement of international normalized ratio (INR)